viewCello Health PLC

Vibrant US sector putting a tailwind behind Cello Health says CEO Scott

A vibrant US healthcare sector is generating good momentum for Cello Health PLC (LON:CLL), says chief executive Mark Scott.

R&D spending and innovation are high, which is driving business towards its healthcare communications and consulting arms.

Existing accounts are growing while the addition of new customers is strong, he told Proactive.

Cello is also generating plenty of cash, he adds and unless it makes another sizeable purchase should finish the year with a healthy balance.

Scott wants to add to the company’s footprint in the US, though he says prices in the US reflect just how strong the market there is at present.

Quick facts: Cello Health PLC

Price: 127 GBX

Market: AIM
Market Cap: £135.03 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cello Health PLC named herein, including the promotion by the Company of Cello Health PLC in any Content on the Site, the Company receives from...



Full interview: Cello Health reports good growth in profits and strong cash flow

Cello Health PLC's (LON:CLL) Mark Scott tells Proactive London they've seen good growth in profits and strong cash flow for the first half of the year said that he's confident about the rest of the year too. The group delivered net revenue of £54.5mln for the first six months of the year,...

on 18/9/19

2 min read